New York, September 12, 2011 – Reval, the leading global provider of corporate financial risk management solutions, announced today that Merck (NYSE:MRK), known as MSD outside the United States and Canada, has selected Reval’s Software-as-a-Service solution to support its foreign exchange and interest rate derivative portfolios.
“We are thrilled to work with such a quality, global company on its initiative to bring together all of its processes for exposure management, derivative management and hedge accounting onto a single, integrated workflow using Reval,” says Jeff Stacey, Reval’s Managing Director, Americas.
Merck and Schering-Plough merged in November 2009 to create a new company that today is the second-largest healthcare company in the world.
For more information about Reval, please contact firstname.lastname@example.org
Other suggested links: twitter.com/revalacctg4risk
For more information, visit www.reval.com or email email@example.com.
Note to editors: Trademarks and registered trademarks remain the property of their respective owners.